使用地拉罗司治疗期间应该注意什么？

(Deferasirox) is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥7mL/kg) in patients with β-thalassemia older than 6 years old; for children under 6 years old and iron overload caused by other transfusion-dependent diseases. Deferasirox is the only oral iron chelator developed by Novartis. So, what should you pay attention to during treatment with Deferasirox?

1. Patients should take it 30 minutes before meals. Take deferasirox (Deferasirox) at the same time every day. 

2. Skin toxicity: Deferasirox may cause rash (dose-related); mild to moderate rashes may resolve without interrupting treatment; for severe rashes, interrupt and consider restarting with dose escalation and lower doses of oral steroids. 

3. Auditory interference: Hearing loss and high-frequency hearing loss have been reported (rarely) with use; perform an auditory test before starting Deferasirox and periodically (every 12 months) during use; if abnormalities occur, monitor closely and consider dose reduction or treatment interruption. 

4. Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have also been reported; the risk of other skin reactions including drug reactions with eosinophilia and systemic symptoms cannot be excluded. 

Myelosuppression: Cytopenia (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) (some fatal) has been reported; patients with pre-existing blood disorders may be at increased risk; monitor blood counts regularly. Interrupt deferasirox therapy in patients who develop cytopenia; may restart once the cause of cytopenia is determined; contraindicated if platelet count <50,000/mm3. 

6. Gastrointestinal events: Gastrointestinal bleeding (including death) may occur; more common in patients with advanced hematological malignancies and/or elderly patients with low platelet counts; discontinue treatment for suspected gastrointestinal bleeding or ulceration. Monitor patients closely for signs/symptoms of gastrointestinal ulceration/bleeding while taking Deferasirox.

The above is the content of (Enrig, Deferasirox) precautions, I hope it can help you!